VS-6063

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BACKGROUND Docetaxel, the standard chemotherapy for metastatic castration-resistant prostate cancer (CRPC) also enhances the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2018
2018
  • 2018
DARMSTADT, Germany & NEW YORK & BOSTON--(BUSINESS WIRE)--Merck, Pfizer and Verastem announced today that they have entered into… (More)
Is this relevant?
2018
2018
The non-receptor cytoplasmic tyrosine kinase, Focal Adhesion Kinase (FAK) is known to play a key role in a variety of normal and… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2017
2017
Because cancer stem cells (CSCs) have been implicated in chemo-resistance, metastasis and tumor recurrence, therapeutic targeting… (More)
Is this relevant?
2016
2016
VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase and proline-rich… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
2016
2016
Methods: In Study B0761001 (n=46), the safety, pharmacokinetics (PK) and pharmacodynamics of single and multiple-doses of VS-6063… (More)
Is this relevant?
2015
2015
Objective VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase (FAK) and… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
2014
2014
Malignant pleural mesothelioma (MPM) is an aggressive tumor in the lining of the lung often resulting from prior exposure to… (More)
  • figure 2
  • figure 1
  • figure 3
Is this relevant?
2013
2013
BACKGROUND We previously found focal adhesion kinase (FAK) inhibition sensitizes ovarian cancer to taxanes; however, the… (More)
Is this relevant?